Microarrays & Multiplexing

CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.

NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements. 

The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014. 

The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.

The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering. 

Nucleic-acid-responsive gel, method for producing same, and use of same
Methods for detection and typing of nucleic acids
Integrated sensor arrays for biological and chemical analysis
Feature intensity reconstruction of biological probe array
Detection of digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer by gene expression profiling
Assays for affinity profiling of nucleic acid binding proteins